Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
01 Agosto 2024 - 3:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced it completed the sale of
its EndoPredict® business to Eurobio Scientific, a leading French
group in in vitro medical diagnostics and life sciences. As
part of the sale, Myriad also licensed Eurobio the right to sell
Prolaris® in vitro diagnostic kits outside of the U.S.
In May 2024, Myriad announced the reorganization of its
International operations to better align company resources to its
domestic opportunities while continuing to serve key biopharma
partners and patients globally. This transaction builds on Myriad's
earlier efforts this year to accelerate profitable business growth
across its portfolio. Myriad has the licensed rights to continue to
produce and sell EndoPredict in the U.S. as part of Precise™
Oncology Solutions, its comprehensive suite of precision medicine
tools for breast, prostate, ovarian, pancreatic, endometrial, and
colon cancer.
“The reorganization of Myriad’s International operations will
enable us to continue growing our oncology and biopharma business
in Europe and Asia, including Japan, through a more efficient
commercial distribution model that reduces organizational
complexity and enterprise risk,” said Paul J. Diaz, President and
CEO, Myriad Genetics.
About EndoPredict Breast Cancer Prognostic
TestEndoPredict is a prognostic test that predicts patient
risk of breast cancer recurrence to help identify who can consider
safely forgoing chemotherapy.
About Prolaris Prostate Cancer Prognostic
TestProlaris is a molecular diagnostic test that provides
personalized information about the aggressiveness of a patient's
prostate cancer.
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
that the company’s reorganization of its International operations
will better align company resources to its domestic opportunities
while continuing to serve key biopharma partners and patients
globally and will enable the company to continue growing its
oncology and biopharma business in Europe and Asia through a more
efficient commercial distribution model that reduces organizational
complexity and enterprise risk. These “forward-looking statements”
are management’s expectations of future events as of the date
hereof and are subject to known and unknown risks and uncertainties
that could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on February 28, 2024, the
company’s Quarterly Report on Form 10-Q filed on May 8, 2024, as
well as any updates to those risk factors filed from time to time
in the company’s Quarterly Reports on Form 10-Q or Current Reports
on Form 8-K. Myriad is not under any obligation, and it expressly
disclaims any obligation, to update or alter any forward-looking
statements, whether as a result of new information, future events
or otherwise except as required by law.
Investor Contact Matt Scalo (801)
584-3532 IR@myriad.com
Media Contact Glenn Farrell (385)
318-3718 PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024